Dravet综合征
克洛巴扎姆
托吡酯
医学
大麻酚
生酮饮食
重症监护医学
癫痫
芬氟拉明
抗惊厥药
麻醉
精神科
大麻
内科学
受体
血清素
作者
J. Helen Cross,Roberto Caraballo,Rima Nabbout,Federico Vigevano,Renzo Guerrini,Lieven Lagae
出处
期刊:Epilepsia
[Wiley]
日期:2019-12-01
卷期号:60 (S3)
被引量:100
摘要
Abstract Over time, with careful delineation of Dravet syndrome, we have gained experience in treatments most likely to lead to improvement in seizures, as well as those that should be avoided. Sodium valproate, clobazam, stiripentol, and topiramate are all medications that may lead to benefit, as well as the ketogenic diet. Bromides may be utilized in resistant cases. However, equally important are outlining prompt rescue treatment for prolonged seizures and avoidance of precipitants. Newer agents including cannabidiol and fenfluramine have been demonstrated to be of benefit in clinical trials. We propose an algorithm for management, but appreciate that the positioning of newer agents is yet to be established.
科研通智能强力驱动
Strongly Powered by AbleSci AI